FDA plans to publish a proposed rule by the end of the year that would require prescription drug advertisements on television, radio and similar broadcast media to include all relevant risk, contraindication and safety information within the advertisement itself, eliminating the longstanding “adequate provision” option.

FDA looks to formalize one of its most significant transparency initiatives in decades: the public release of Complete Response Letters issued to companies whose drug applications are rejected.